… coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory
syndrome coronavirus … of COVID-19 in the form of post and long- COVID syndromes, posing a …

… of COVID‐19 patients, we randomly enrolled 20 patients with critical COVID‐19 entering
the … for 15 to 20 days and received a prophylactic dose of low molecular weight heparin (LMWH) …

… Until clinical trial data are available, our results provide strong evidence for the use of
prophylactic anticoagulation as initial therapy for COVID-19 patients upon hospital admission. …

… was COVID-19 … therapies for COVID-19 at prophylactic or therapeutic doses; 4) the comparator
was placebo or standard of care, with or without other concomitant therapies for COVID-19…

… therapeutic dose LMWH or unfractionated heparin is confined to patients with moderate
covid-19; … severe covid-19, and intermediate versus therapeutic thromboprophylaxis in moderate …

… therapy to treat critically ill patients globally [5, 31, 32]. Therefore, there is a need for the
development of effective and safe COVID-19-specific vaccines or therapeutic … as a therapy based …

… This review provides an overview of the current evidence on (H)CQ therapy in patients with
COVID-19 and discusses different strategies for prophylactic (H)CQ therapy (ie, preinfection, …

… is currently recommended for patients hospitalized with COVID‐19. The aim of this … therapy
with aspirin over prophylactic anticoagulation (PAC) in patients hospitalized with COVID‐19 …

… the treatment of COVID-19 that emphasize urgency around distinctive effective therapies. This
… with COVID 19 infection, as well as prophylaxis of health care and/ or household contacts. …

… This review discusses different therapeutic approaches for CoVs, focusing on the
implementations of nanomedicine to contain COVID-19 and related pathogenic CoVs. Coronavirus …